Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen and Vorinostat for HIV-1 Latency Reversal
NCT03382834Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of tamoxifen in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Started Apr 2018; status: completed.
02
Drugs
tamoxifen
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03382834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382834.